Fundraising Fox
/People
Sign in

Anna French

Board director at Renasant Bio · Board director at Entact Bio · Board director at Auron Therapeutics

Cambridge, Massachusetts, United States

Find your path to Anna

102 people in our graph share verified history with Anna — schools, employers, funds. One of them is your warm intro.

Ronald MartellunlockedAnna: together at Jasper Therapeutics (2022–2024)
×2Anna: together at Jasper Therapeutics
Anna: together at WindMIL Therapeutics
×2Anna: together at Talaris Therapeutics

About

Anna French, D.Phil., is Managing Partner at Qiming Venture Partners USA, which she joined in 2017 from the Boston Consulting Group, where she advised pharmaceutical and biotech companies on strategy and operations with a focus on cell therapy and regenerative medicine. She previously led the CASMI Translational Stem Cell Consortium, an industry-academic partnership between Oxford University and University College London focused on translating scientific innovation into the clinic. French holds a D.Phil. from the University of Oxford, where her research addressed the hematological differentiation of human induced pluripotent stem cells, and a BSc in Biochemistry from the University of Bristol; she has authored over 20 publications in stem cell research.

Board director at Renasant Bio

Intro paths

→

In turn, Anna can intro founders to Renasant Bio's investors below.

Renasant Bio's investors · 4

5AM VenturesSan Francisco · $100K – $4M checks · since 2025Atlas VentureCambridge · $500K – $1M checks · since 2025OrbiMedNew York · $1M – $75M checks · since 2025Qiming Venture Partners USACambridge · since 2025

Co-founders at Renasant Bio

JR
Jeremy ReiterScientific Co-Founder
MD
Markus DellingScientific Co-Founder

Board director at Entact Bio

Intro paths

→

In turn, Anna can intro founders to Entact Bio's investors below.

Entact Bio's investors · 3

AbingworthLondon · $15M – $30M checks · since 2022venBio Global StrategicSan Francisco · since 2026venBio PartnersSan Francisco · since 2026

Board director at Auron Therapeutics

Intro paths

→

In turn, Anna can intro founders to Auron Therapeutics's investors below.

Auron Therapeutics's investors · 4

Apollo Health VenturesBerlin · since 2022DCVC (Data Collective)Palo Alto · $5M – $25M checksDCVC BioPalo Alto · since 2022Polaris PartnersBoston · $500K – $5M checks · since 2025

Co-founders at Auron Therapeutics

KY
Katharine YenExecutive Officer, Director
KYKate Yen
Kate YenFounder

Experience

  1. Qiming Venture Partners USAManaging Partnercurrent2017 — presentGreater Boston
  2. Altis LabsBoard Directorcurrent2026 — presentToronto, Ontario, Canada
  3. Renasant BioBoard Directorcurrent2025 — presentSan Francisco Bay Area
  4. Montage BioBoard Directorcurrent2023 — presentNew York City Metropolitan Area
  5. Empirico Inc.Board Directorcurrent2023 — presentSan Diego, California, United States
  6. Entact BioBoard Directorcurrent2023 — presentBoston, Massachusetts, United States
  7. Umoja BiopharmaBoard Directorcurrent2020 — presentSeattle, Washington, United States
  8. Auron TherapeuticsBoard Directorcurrent2020 — presentBoston, Massachusetts, United States
  9. Tenpoint Therapeutics LtdBoard Director2020 — 2024London Area, United Kingdom
  10. Jasper TherapeuticsBoard Director2019 — 2024
  11. WindMIL TherapeuticsBoard Director2018 — 2023Washington DC-Baltimore Area
  12. Talaris TherapeuticsBoard Observer2018 — 2021
  13. Cadent TherapeuticsBoard Observer2018 — 2021Cambridge, MA
  14. LetsGetCheckedBoard Observer2018 — 2020New York City Metropolitan Area
  15. The Boston Consulting GroupManagement Consultant2014 — 2017Boston, US / London, UK
  16. Centre for the Advancement of Sustainable Medical Innovation (CASMI)Manager- CASMI Translational Stem Cell Consortium2012 — 2014Greater Oxford Area
  17. University of OxfordGraduate Researcher2009 — 2013Greater Oxford Area

Skills & more

Science13Literature Reviews3Research25Statistics7Teaching6Molecular Biology21Qualitative Research3Flow Cytometry4Cell Biology6Biotechnology29Stem Cells12Biomedical Engineering3
+6 moreClinical ResearchLifesciencesLife SciencesData AnalysisCell CultureManagement

From Anna's professional profile.

Frequently asked questions

Who is Anna French?
Anna French, D.Phil., is Managing Partner at Qiming Venture Partners USA, which she joined in 2017 from the Boston Consulting Group, where she advised pharmaceutical and biotech companies on strategy and operations with a focus on cell therapy and regenerative medicine. She previously led the CASMI Translational Stem Cell Consortium, an industry-academic partnership between Oxford University and University College London focused on translating scientific innovation into the clinic. French holds a D.Phil. from the University of Oxford, where her research addressed the hematological differentiation of human induced pluripotent stem cells, and a BSc in Biochemistry from the University of Bristol; she has authored over 20 publications in stem cell research.
Where does Anna French work?
Anna French is Board director at Renasant Bio and Board director at Entact Bio and Board director at Auron Therapeutics.
Where did Anna French go to school?
Anna French studied at University of Oxford (PhD, Clinical and Laboratory Sciences); University of Bristol (BSc, Biochemistry).

Same school

Shared employers